Beyond LDL: Targeting ANGPTL3 to Reduce Residual Cardiovascular Risk

IF 21.7 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of the American College of Cardiology Pub Date : 2025-03-31 DOI:10.1016/j.jacc.2025.03.502

Dirk J. Blom, Daniel Gaudet

引用次数: 0

Abstract

Section snippets

Funding Support and Author Disclosures

Dr Blom has received research grants or consulting fees from Regeneron, Amryt, Arrowhead, Esperion, Ionis, Merck, Novartis, and Verve Therapeutics; and has patients who are receiving compassionate use Evinacumab from Ultragenyx. Dr Gaudet has received research grants or consulting fees from Regeneron, Amgen, Amryt, Arrowhead, CRISPRx, Eli Lilly, Esperion, Merck, New Amsterdam pharma, Novartis, Ultragenyx, and Verve Therapeutics; and has received research grant payments through ECOGENE-21, an

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the American College of Cardiology 医学-心血管系统

CiteScore

42.70

自引率

3.30%

发文量

5097

审稿时长

2-4 weeks

期刊介绍： The Journal of the American College of Cardiology (JACC) publishes peer-reviewed articles highlighting all aspects of cardiovascular disease, including original clinical studies, experimental investigations with clear clinical relevance, state-of-the-art papers and viewpoints. Content Profile: -Original Investigations -JACC State-of-the-Art Reviews -JACC Review Topics of the Week -Guidelines & Clinical Documents -JACC Guideline Comparisons -JACC Scientific Expert Panels -Cardiovascular Medicine & Society -Editorial Comments (accompanying every Original Investigation) -Research Letters -Fellows-in-Training/Early Career Professional Pages -Editor’s Pages from the Editor-in-Chief or other invited thought leaders